Can-Fite's Namodenoson Clears Phase IIa Safety Bar in Pancreatic Cancer

Overview

• Can-Fite reported its open-label Phase IIa trial in advanced PDAC met the primary safety endpoint with no new safety signals.
• Twenty heavily pretreated patients were enrolled, including many with metastatic disease and multiple prior lines of therapy.
• Roughly one-third of participants were alive at the data cut-off, with overall survival and progression-free survival still maturing.
• The company plans to present more complete survival outcomes at upcoming scientific meetings.
• Namodenoson is a selective A3 adenosine receptor agonist with FDA Orphan Drug Designation for pancreatic cancer, and CANF shares roughly doubled after the news, according to market reports.